What we do Corona Remedies Ltd manufactures and markets pharmaceutical products focused on women's healthcare, cardio-diabetes, pain management, and urology sectors. |
Founded in 2,004 |
Market share Ranks #5 in women's healthcare and pain management, #9 in urology, and growing rapidly with a 1.82x IPM growth rate. |
Problem solved Provides effective and affordable medicines addressing chronic diseases and women's health issues. |
Top clients or who we serve Serves hospitals, infertility specialists, IVF centers, and a wide network across India - B2B and B2C. |
Key management Niravkumar Kritikumar Mehta (MD & CEO), Ankur Kritikumar Mehta (Joint MD), Viral Bhupendrabhai Sitwala (Whole-Time Director). |
Our journey and innovations Founded in 2004 with multiple divisions launched over years; acquired key brands and upgraded manufacturing with GMP certifications. |
Where we operate Primarily in India with export presence in Eurasian markets including Russia and Kazakhstan. |
Top products or what we offer Offers brands like Myoril (pain management), Tricium (gynecology), Cortel (cardiac), and Obimet (anti-diabetic). |
Top brands Myoril (#5 pain management), Tricium (gynecology), Cortel (cardiac), Obimet (anti-diabetic), Stelbid, Vitneurin. |
Raw materials needed APIs for hormone-based and other pharmaceutical formulations. |
Raw materials supplier Backward integration via investment in La Chandra Pharma labs for APIs. |
Recurring vs cyclical contribution Revenue largely recurring from established chronic therapy portfolios. |
Our industry position Strong presence in Indian pharma market with chronic therapies contributing 71.6% of revenue. |
Financial highlights FY25 revenue Rs.1196 crore, Net Profit Rs.149 crore, EBITDA margin 20.1%, PAT margin 12.5%. |
Geographical revenue split 96.3% India, 3.7% Outside India (mainly Eurasian markets). |
Order book - |
Whats driving growth Brand building, expanded medical representative coverage, strategic acquisitions, and export market certifications. |
Our future plans Expand presence in nephrology, CNS, oncology; deepen chronic portfolio; enter regulated overseas markets. |
Our green promise Uses solar power, zero liquid discharge, tree plantation, promotes gender equality, and has EDGE Advance certification. |
Our people and values Diverse workforce with 40% female employees in Solan plant; focus on training and corporate culture. |
Key challenges ahead Competitive pharma landscape, regulatory compliance, and scaling regulated market presence. |
Interesting facts Certified EU-GMP plant, EDGE Advance certified for energy and water saving, strong growth outpacing industry. |
Risks and strategy Mitigates market competition risk via acquisitions and R&D; compliance and quality certifications as strategy. |
